SMARCB1 and schwannoma: In a total of 153 patients aged younger than 24 years with an isolated schwannoma, genetic testing indicated that 15 (9.8%) patients had a germline NF2 pathogenic variant, six patients (3.9%) had a germline SMARCB1 PV, and 10 patients (6.5%) had a germline LZTR1 PV [96].